Literature DB >> 14971870

Prognostic significance of hemostatic parameters in patients with lung cancer.

Ebru Unsal1, Figen Atalay, Sükran Atikcan, Aydin Yilmaz.   

Abstract

There is a subclinical activation of coagulation and fibrinolysis system in lung cancer. Alterations in hemostatic system are seen frequently in lung cancer correlated with the prognosis of disease. In this prospective study, our purpose was to investigate the prognostic significance of hemostatic markers in patients with lung cancer. The study comprised 58 patients (22 squamous cell carcinoma, 16 adenocarcinoma, 20 small cell carcinoma). There were 55 men (95%)and 3 women (5%) with a mean age of 61 years range (36-74). Plasma level of platelets (PLT), prothrombin time (PT), active partial thromboplastin time (aPTT), antithrombin III (AT III), fibrinogen (F) and D-dimer level were measured before the initiation of any therapy. Patients were followed up for 17 (12-20) months. The median survival was determined as 6.4 months. Three histopathologic groups; squamous cell carcinoma, adenocarcinoma and small cell carcinoma were compared for the hemostatic parameters. There were no statistically significant differences among the histopathologic types for any of the parameters (P > 0.05). Patients were divided into two groups as patients without distant metastasis (stages I,II,III) and with distant metastasis (stage IV). The group with distant metastasis had higher level of D-dimer than the other group (P < 0.05). However, there were no statistically significant differences for D-dimer level between stages IIIB and IV (P > 0.05). Patients having high D-dimer and low AT III level had poor survival in our study. Thus, high level of D-dimer and low AT III level were determined as correlated with short survival (P < 0.05). These results suggest that elevated plasma level of D-dimer and low AT III level might be a sign of poor prognosis in patients with lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971870     DOI: 10.1016/j.rmed.2003.07.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

1.  Prognostic role of D-dimer in patients with lung cancer: a meta-analysis.

Authors:  Xuelei Ma; Yanyan Li; Jing Zhang; Jingwen Huang; Lei Liu
Journal:  Tumour Biol       Date:  2013-10-10

2.  Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis.

Authors:  Xi Zhang; Yuge Ran
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

Authors:  Julien Cherfils-Vicini; Sophia Platonova; Mélanie Gillard; Ludivine Laurans; Pierre Validire; Rafaele Caliandro; Pierre Magdeleinat; Fathia Mami-Chouaib; Marie-Caroline Dieu-Nosjean; Wolf-Herman Fridman; Diane Damotte; Catherine Sautès-Fridman; Isabelle Cremer
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

4.  Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.

Authors:  Xia Liu; Xiaogang Chen; Jiezuan Yang; Renyong Guo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

5.  Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer.

Authors:  Sung Kyu Hong; Dong Woo Ko; Juhyun Park; In Sung Kim; Seung Hwan Doo; Cheol Yong Yoon; Hongzoo Park; Won Ki Lee; Dae Sung Kim; Seong Jin Jeong; Seok-Soo Byun; Sang Eun Lee
Journal:  Korean J Urol       Date:  2010-01-21

6.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

7.  High plasma D-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis.

Authors:  Yong-Xin Zhou; Zhong-Min Yang; Jing Feng; Ying-Jun Shan; Wei-Li Wang; Yun-Qing Mei
Journal:  Tumour Biol       Date:  2013-07-20

8.  Comparison of the serum fibrin-fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer.

Authors:  Hee Jin So; Seok-Il Hong; Jin Kyung Lee; Yoon Hwan Chang; Sun Jung Kang; Young Jun Hong
Journal:  Biomed Rep       Date:  2014-07-11

9.  [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis].

Authors:  C Aulmann; P Seufert; M Sandherr; G Schlimok; R Schulze; D Oruzio
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

10.  Coagulation tests show significant differences in patients with breast cancer.

Authors:  Faruk Tas; Leyla Kilic; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2014-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.